Lipella Pharmaceuticals (LIPO) Competitors $0.78 -0.04 (-4.85%) As of 07/3/2025 12:40 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. PMN, HOTH, NKGN, CASI, LEXX, ALLR, EDSA, BFRG, SYBX, and RLYBShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Promis Neurosciences (PMN), Hoth Therapeutics (HOTH), NKGen Biotech (NKGN), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), Allarity Therapeutics (ALLR), Edesa Biotech (EDSA), Bullfrog AI (BFRG), Synlogic (SYBX), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. Its Competitors Promis Neurosciences Hoth Therapeutics NKGen Biotech CASI Pharmaceuticals Lexaria Bioscience Allarity Therapeutics Edesa Biotech Bullfrog AI Synlogic Rallybio Promis Neurosciences (NASDAQ:PMN) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk. Which has stronger valuation and earnings, PMN or LIPO? Promis Neurosciences has higher earnings, but lower revenue than Lipella Pharmaceuticals. Promis Neurosciences is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPromis NeurosciencesN/AN/A$2.78M-$0.05-9.26Lipella Pharmaceuticals$536.36K6.50-$5.02M-$4.08-0.19 Do analysts prefer PMN or LIPO? Promis Neurosciences currently has a consensus price target of $4.50, indicating a potential upside of 871.92%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Promis Neurosciences is more favorable than Lipella Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PMN or LIPO more profitable? Promis Neurosciences has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Promis Neurosciences' return on equity of -186.19% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Promis NeurosciencesN/A -186.19% -98.56% Lipella Pharmaceuticals -988.83%-224.08%-172.88% Does the media favor PMN or LIPO? In the previous week, Promis Neurosciences' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score. Company Overall Sentiment Promis Neurosciences Neutral Lipella Pharmaceuticals Neutral Do insiders and institutionals believe in PMN or LIPO? 50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 6.1% of Promis Neurosciences shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, PMN or LIPO? Promis Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. SummaryPromis Neurosciences beats Lipella Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.48M$2.90B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-0.1921.5627.5820.25Price / Sales6.50281.07417.23118.60Price / CashN/A42.7336.8958.07Price / Book0.497.518.035.67Net Income-$5.02M-$55.05M$3.18B$249.21M7 Day Performance-13.33%4.61%2.91%3.28%1 Month Performance-74.76%4.72%3.72%5.56%1 Year Performance-78.80%5.92%36.04%21.13% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella Pharmaceuticals1.3523 of 5 stars$0.78-4.9%N/A-77.9%$3.48M$536.36K-0.194Gap DownPMNPromis Neurosciences3.3919 of 5 stars$0.48-1.2%$4.50+841.4%-71.2%$15.63MN/A-9.565Gap UpHOTHHoth Therapeutics1.5916 of 5 stars$1.17+0.2%$4.00+241.3%+34.6%$15.39MN/A-1.024Analyst UpgradeNKGNNKGen BiotechN/A$0.34+2.7%N/A-77.1%$15.24MN/A-0.07N/ACASICASI Pharmaceuticals4.1384 of 5 stars$1.23+4.1%$4.00+225.7%-74.7%$15.08M$28.54M-0.48180Positive NewsLEXXLexaria Bioscience2.8897 of 5 stars$0.85-1.8%$5.00+485.5%-66.1%$15.00M$460K-1.457News CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionALLRAllarity Therapeutics1.1247 of 5 stars$0.97-3.8%N/A-83.1%$14.66MN/A0.0010EDSAEdesa Biotech1.5947 of 5 stars$2.05+1.0%$5.00+143.9%-49.5%$14.39MN/A-1.2920Positive NewsBFRGBullfrog AI0.9413 of 5 stars$1.53+1.0%N/A+0.0%$14.37M$60K-1.884News CoveragePositive NewsSYBXSynlogic0.5241 of 5 stars$1.21-4.7%N/A-18.1%$14.16M$10K-0.4880Gap UpRLYBRallybio2.1916 of 5 stars$0.33-1.5%$10.00+2,903.0%-73.6%$13.86M$640K-0.3140 Related Companies and Tools Related Companies PMN Competitors HOTH Competitors NKGN Competitors CASI Competitors LEXX Competitors ALLR Competitors EDSA Competitors BFRG Competitors SYBX Competitors RLYB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
